Expertos Invitados





NUEVAS RECOMENDACIONES EN LA PREVENCION DE INFECCIONES OPORTUNISTAS ENTRE RECEPTORES DE TRASPLANTES DE CELULAS MADRE HEMATOPOYETICAS

(especial para SIIC © Derechos reservados)
Se destaca la importancia de la prevención con aciclovir en pacientes con Herpes simplex, la utilidad del ganciclovir en la profilaxis del citomegalovirus, el uso de fluconazol para combatir la candidiasis, la profilaxis con TMP-SMZ en la neumonía por Pneumocystis y el esquema de vacunación a seguir en pacientes que reciben trasplantes.
dykewicz.jpg Autor:
Clare a. Dykewicz
Columnista Experto de SIIC
Artículos publicados por Clare a. Dykewicz
Recepción del artículo
6 de Agosto, 2003 		Aprobación
9 de Septiembre, 2003
Primera edición
6 de Noviembre, 2003 		Segunda edición, ampliada y corregida
7 de Junio, 2021

NUEVAS RECOMENDACIONES EN LA PREVENCION DE INFECCIONES OPORTUNISTAS ENTRE RECEPTORES DE TRASPLANTES DE CELULAS MADRE HEMATOPOYETICAS

Resumen
Las "Recomendaciones para la prevención de infecciones oportunistas en receptores de trasplantes de células madre hematopoyéticas", publicadas por los CDC (Centers for Disease Control and Prevention) y la American Society for Blood and Marrow Transplantation de los EE.UU. en 2000, proveen recomendaciones basadas en la evidencia para evitar infecciones entre los pacientes con trasplante de células madre hamatopoyéticas (TCMH). Las recomendaciones clave incluyen la administración de (1) aciclovir a todos los pacientes seropositivos para virus Herpes simplex con trasplante alogénico de TCMH, como prevención de la reactivación del HSV durante el período temprano posterior al trasplante; (2) profilaxis con ganciclovir o terapia preventiva a todos los pacientes con trasplante alogénico de TCMH con riesgo de contraer enfermedad por citomegalovirus desde el día del injerto hasta el día 100 posterior al trasplante; (3) 400 mg por día de fluconazol vía oral o intravenosa para la prevención de infección por especies de Candida susceptibles a dicho antibiótico en receptores alogénicos de TCMH; y (4) profilaxis para la neumonía por Pneumocystis a todos los pacientes con TCMH durante todos los períodos de inmunocompromiso luego del injerto. Las pautas también recomiendan la vacunación contra difteria, tétanos, tos convulsa o tétanos difteria; polio; H. influenzae y hepatitis B en estos pacientes a los 12, 14 y 24 meses postrasplante. La vacunación contra sarampión, paperas y rubéola debe retrasarse hasta cumplidos los 24 meses del trasplante y se debe reservar para pacientes que se supone que son inmunocompetentes. Se recomienda en receptores de TCMH la administración de por vida en forma anual de la vacuna inactiva contra la gripe.

Palabras clave
Trasplante de células madre hematopoyéticas, infecciones oportunistas, infección por citomegalovirus, infección por virus Herpes simplex


Artículo completo
(castellano)
Extensión:  +/-14.24 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

UPDATE ON THE GUIDELINES FOR PREVENTING OPORTUNISTIC INFECTIONS AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

Abstract
The "Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients," published in 2000 by the Centers for Disease Control and Prevention (CDC) and the American Society for Blood and Marrow Transplantation, provides evidence-based recommendations for preventing infections among hematopoietic stem cell transplant (HSCT) recipients. Key recommendations include administering 1) acyclovir to all herpes simplex virus (HSV)-seropositive allogeneic HSCT recipients to prevent HSV reactivation during the early post-transplant period, 2) ganciclovir prophylaxis or pre-emptive therapy to all allogeneic HSCT recipients at risk for cytomegalovirus disease from engraftment to day +100 post-HSCT, 3) fluconazole 400 mg/day po. or i.v. to prevent infection from fluconazole-susceptible Candida species in allogeneic HSCT recipients, and 4) prophylaxis for Pneumocystis pneumonia to all allogeneic HSCT patients throughout all periods of immunocompromise after engraftment. The guidelines also recommend giving diphtheria, tetanus, acellular pertussis or tetanus-diphtheria; inactivated polio; H. influenzae; and hepatitis B vaccines to HSCT recipients at 12, 14, and 24 months post-HSCT. Administration of the measles, mumps, rubella vaccine should be delayed until 24 months post-HSCT and should be reserved for HSCT recipients who are presumed immunocompetent. Lifelong seasonal administration of inactivated influenza vaccine is recommended for HSCT recipients.

Key words
Trasplante de células madre hematopoyéticas, infecciones oportunistas, infección por citomegalovirus, infección por virus Herpes simplex


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Infectología
Relacionadas: Epidemiología, Hematología, Medicina Interna, Salud Pública



Comprar este artículo
Extensión: 14.24 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
    1.
  1. CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49(No. RR-10):1-125 and Biol Blood and Marrow Transplant 2000;6(6a):659-734.2.
  2. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44. (No. RR-8);1-34.3.
  3. CDC. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997;46(No. RR-12):1-46.4.
  4. CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999;48(No. RR-10):1-66.5.
  5. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001;33:139-44.6.
  6. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996(4):23:795-805.7.
  7. Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer-is it justified [Letter] Clin Infect Dis 1997;25(2):346-8.8.
  8. Bowden RA, Myers JD. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. 3rd edition. New York, NY:Plenum Medical Book Co. 1994:601-628.9.
  9. Cometta A, Calandra T, Billie J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenias. N Engl J Med 1994;330(17):1240-1241.10.
  10. Kessinger A, Armitage JO. Use of peripheral stem cell support of high-dose chemotherapy. In: DeVita VT Jr., Hellman S, Rosenberg SA, eds. Important advances in oncology 1993. Philadelphia, PA:J.B. Lippincott Co. 1993.11.
  11. Rand KJ, Houck H, Ganju A, Babington RG, Elfenbein GJ. Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous immunoglobulin in bone marrow transplant patients. Bone Marrow Transplant 1989;4(6):679-683.12.
  12. Bosi A, De Majo E, Guidi S, et al. Kinetics of anti-CMV antibodies after administration of intravenous immunoglobulins to bone marrow transplant recipients. Haematologica 1990;75(2):109-112.13.
  13. Buckley RH, Schiff RI. Use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325(2):110-107.14.
  14. Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes simplex infections. N Engl J Med 1981;305:63-67.15.
  15. Gluckman E, Lotsberg J, Devergie A, et al. Prophylaxis of herpes infections after bone marrow transplantation by oral acyclovir. Lancet 1983;2:706-708.16.
  16. Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann Intern Med 1982;96:265-269.17.
  17. Wade JC, Newton B, Flournoy N. et al. Oral acyclovir for prevention of herpes simplex reactivation after marrow transplantation. Ann Intern Med 1984;100:823-828.18.
  18. Johnson JR, Egaas S, Gleaves CA. Hepatitis due to herpes simplex virus in marrow-transplant recipients. Clin Infect Dis 1992;14:38-45.19.
  19. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000;31:927-935.20.
  20. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002;185:273-282.21.
  21. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 1995;86:3598-3603.22.
  22. Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:633-638.23.
  23. Boeckh M, Stevens-Ayers T, Bowden R. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996;174(5):907-912.24.
  24. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double blind study. Blood 1996;88(10):4063-4071.25.
  25. Boeckh M, Bowden R. Cytomegalovirus infection in marrow transplantation. In: Buckner CD, Clift RA, eds. Technical and Biological Components of Marrow Transplantation. Boston, MA: Kluwer Academic Publishers, 1995: 97-136.26.
  26. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effect of antiviral therapy after bone marrow transplantation. Blood 1995;86(7):2815-2820.27.
  27. Mendez JC, Sia IG, Paya CV. Human cytomegalovirus. In: Lennette EH, Smith TF, eds. Laboratory diagnosis of viral infections. 3d ed., revised and expanded. New York, NY: Marcel Decker, Inc., 1999;361-372.28.
  28. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N Engl J Med 1991;325(23):1601-1607.29.
  29. Schmidt GM, Horak DA, Niland JC, et al. Randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324(15):1005-1011.30.
  30. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118(3):173-178.31.
  31. Limaye AP, Huang M-L, Leisenring W, et al. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis 2001;183:377-382.32.
  32. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407-414.33.
  33. Wolf DG, Lurain NS, Zuckerman T, et al. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell recipients. Blood 2003;101:463-465.34.
  34. Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002;35:999-1004.35.
  35. Goodman JL, Winston DJ, Greenfield R, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.36.
  36. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552.37.
  37. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96(6):2055-2061.38.
  38. Fukuda T, Boeckh M, Carter RA, et al. Invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation after nonmyeloablative conditioning: risks and outcomes. Blood First Edition Paper, prepublished online April 10, 2003; DOI 10.1182/blood-2003-02-0456. URL: www.bloodjournal.org39.
  39. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989;5(2):131-142.40.
  40. CDC. Guidelines for prevention of nosocomial pneumonia. Respiratory Care 1994;39(12):1191-1236.41.
  41. Rhame FS, Streifel AJ, Kersey JH Jr, McGlave PB. Extrinsic risk factors for pneumonia in the patient at high risk of infection [Review]. Am J Med 1984;76(5A):42-52.42.
  42. The American Institute of Architects Academy of Architecture for Health, The Facilities Guidelines Institute, with assistance from the U.S. Department of Health and Human Services. Guidelines for design and construction of hospital and health care facilities, Washington, DC: American Institute of Architects, 2001:81.43.
  43. Streifel AJ, Marshall JW. Parameters for ventilation controlled environments in hospitals. In: Moschandreas DJ, ed. Design, construction, and operation of health buildings; solutions to global and regional concerns. Atlanta, GA: American Society of Heating, Refrigerating and Air-Conditioning Engineers Press, 1998;305-309.44.
  44. Streifel AJ. Chapter 80: Design and maintenance of hospital ventilation systems and the prevention of airborne nosocomial infections. In: Mayhall CG, ed. Hospital epidemiology and infection control. 2nd ed. Philadelphia, PA:Lippincott Williams & Wilkins 1999;1211-1221.45.
  45. Rask DR, Dziekan B, Swincicki WC, et al. Air quality control during renovation in health care facilities. In: Moschandreas DJ, ed. Design, construction, and operation of healthy buildings; solutions to global and regional concerns. Atlanta, GA: American Society of Heating, Refrigerating, and Air-Conditioning Engineers Press, 1998:291-304.46.
  46. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogens molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003;101:2542-2546.47.
  47. Wald A, Leisenring W, van Burik J-A, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-1466.48.
  48. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.49.
  49. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002;29:15-19.50.
  50. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.51.
  51. Martino R, Subirá M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116(2):475-482.52.
  52. BMT CTN. www. Bmtctn.net accessed April17, 2003.53.
  53. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerging Infectious Diseases 2002;8(9):891-896.54.
  54. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10:267-272.55.
  55. Maltezou HC, Petropoulos D, Choroszy M, et al. Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation [Review]. Bone Marrow Transplant 1997;20(10)879-881.56.
  56. Link H, Vöhringer H-F, Wingen F, et al. Pentamidine aerosol prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 1993;11(5):403-406.57.
  57. Souza JP, Boeckh M, Gooley TA, Flowers MED, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999;29:1467-1471.58.
  58. Vasconcelles MJ, Bernardo MVP, King C, Weller EA, Antin JH. Aerosolized pentamidine as Pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol of Blood and Marrow Transplant 2000;6:35-43.59.
  59. Colby C, McAfee SL, Sackstein R, et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24:897-902.60.
  60. Castagnola E, Dini G, Lanino E, et al. Low CD4 count in a patient with P. carinii pneumonia after autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:977-978.61.
  61. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplant 1994;57(5):677-684.62.
  62. Pauksen K, Hammarström V, Ljungman P, et al. Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994;18(4):547-552.63.
  63. Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant 1992;9(6):427-432.64.
  64. Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Responses to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990;162(2):496-500.65.
  65. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989;159(4):610-615.66.
  66. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003;101(3):831-836
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008